Breast cancer prevention for survivors edges forward

Kudos to the New England Journal of Medicine for its early website posting today of a study that will be of interest to breast cancer survivors and their doctors.

The large, double-blind, placebo-controlled study showed cancer-prevention promise for letrozole therapy for women who have taken tamoxifen for five years. There are downsides and unanswered questions, but patients and doctors now have immediate access to the full text of the study and two accompanying editorials.

More information: good.